• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Armstrong, Anne C
    Clay, Vanessa
    Affiliation
    Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road Manchester M20 4BX, UK
    Issue Date
    2019
    
    Metadata
    Show full item record
    Abstract
    Breast cancer remains a leading cause of death worldwide. Our increased understanding of cellular mechanisms inherent to cancer has led to the development of new therapeutic targets. One such therapy is that of poly(ADP-ribose) polymerase (PARP) inhibitors, with PARP playing a key role in the repair of single stranded DNA breaks. The development of drugs able to inhibit PARP led to their investigation in tumors that have defective DNA repair, including that of BRCA1/2-associated cancers. The PARP inhibitor Olaparib, has recently been evaluated in the Phase III OlympiAD trial, and demonstrated a significant progression-free survival advantage in patients with HER2-negative metastatic breast cancer and a germline BRCA-mutatioN This article will review the findings and potential implications of the trial.
    Citation
    Armstrong AC, Clay V. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial. Future Oncol. 2019;15(20):2327-35.
    Journal
    Future Oncology
    URI
    http://hdl.handle.net/10541/622050
    DOI
    10.2217/fon-2018-0067
    PubMed ID
    31304797
    Additional Links
    https://dx.doi.org/10.2217/fon-2018-0067
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.2217/fon-2018-0067
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    • Authors: Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J, Collaborating Investigators
    • Issue date: 2021 Jul
    • Olaparib for the treatment of breast cancer.
    • Authors: Griguolo G, Dieci MV, Guarneri V, Conte P
    • Issue date: 2018 Jun
    • Olaparib Keeps Hereditary Breast Tumors in Check.
    • Issue date: 2017 Aug
    • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    • Authors: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P
    • Issue date: 2017 Aug 10
    • BRCA1/2 testing: therapeutic implications for breast cancer management.
    • Authors: Tung NM, Garber JE
    • Issue date: 2018 Jul
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.